Business Context and Reporting Period
This Form 8-K was filed by Genprex, Inc. on November 2, 2018, reporting a corporate governance event that occurred on the same date. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the approval of a revised compensation policy for non-employee directors.
Material Changes
The Board of Directors approved a Revised Outside Director Compensation Policy. Key changes include:
- Equity Grants: Non-employee directors will receive an annual grant of $80,000 worth of common stock options. These vest in full on the first anniversary of the grant date or the day before the next annual meeting, whichever is earlier. Unvested awards accelerate upon a change of control if the director remains in service.
- Cash Retainers:
- General Board service: $40,000 annually.
- Audit Committee Chair: $20,000 annually.
- Audit Committee Member: $10,000 annually.
- Compensation Committee Chair: $10,000 annually.
- Compensation Committee Member: $5,000 annually.
- Nominating and Corporate Governance Committee Chair: $10,000 annually.
- Nominating and Corporate Governance Committee Member: $5,000 annually.
- Payment Terms: Cash retainers are paid quarterly in arrears on a pro-rated basis. Travel expenses continue to be reimbursed.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The only unusual item noted is the structural change to director compensation, which increases potential equity dilution and cash compensation obligations for the Board.
Investor Verification Checklist
- Verify the total number of non-employee directors to calculate the aggregate annual cash and equity cost of the new policy.
- Review the specific terms of the stock options (e.g., strike price, expiration) in the attached Exhibit 10.1.
- Assess the impact of the $80,000 annual equity grant per director on potential share dilution.
- Confirm if any directors were appointed or elected recently to determine if pro-rated grants apply immediately.